Business Description
Swedish Orphan Biovitrum AB
ISIN : SE0000872095
Compare
Compare
Traded in other countries / regions
SOBI.Sweden0MTD.UKSWOBY.USAB6E.GermanySOBI.Mexico IPO Date
2013-10-22Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 2.83 | |||||
| Interest Coverage | 3.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.5 | |||||
| 3-Year EBITDA Growth Rate | 1.1 | |||||
| 3-Year EPS without NRI Growth Rate | -2.5 | |||||
| 3-Year Book Growth Rate | 15.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 30.97 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.05 | |||||
| 9-Day RSI | 42.43 | |||||
| 14-Day RSI | 42.06 | |||||
| 6-1 Month Momentum % | 28.17 | |||||
| 12-1 Month Momentum % | 4.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | |||||
| Quick Ratio | 0.46 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 275.87 | |||||
| Days Sales Outstanding | 76.83 | |||||
| Days Payable | 71.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | -18.79 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.43 | |||||
| Operating Margin % | 18.9 | |||||
| Net Margin % | 10.89 | |||||
| FCF Margin % | -2.25 | |||||
| ROE % | 7.98 | |||||
| ROA % | 3.63 | |||||
| ROIC % | 4.86 | |||||
| ROC (Joel Greenblatt) % | 905.57 | |||||
| ROCE % | 8.1 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.13 | |||||
| Forward PE Ratio | 26.67 | |||||
| PE Ratio without NRI | 29.8 | |||||
| Shiller PE Ratio | 35.53 | |||||
| Price-to-Owner-Earnings | 230.45 | |||||
| PEG Ratio | 3.92 | |||||
| PS Ratio | 3.74 | |||||
| PB Ratio | 2.54 | |||||
| Price-to-Operating-Cash-Flow | 18.35 | |||||
| EV-to-EBIT | 26.13 | |||||
| EV-to-Forward-EBIT | 21.93 | |||||
| EV-to-EBITDA | 14.67 | |||||
| EV-to-Forward-EBITDA | 12.45 | |||||
| EV-to-Revenue | 4.81 | |||||
| EV-to-Forward-Revenue | 4.54 | |||||
| EV-to-FCF | -222.57 | |||||
| Price-to-Projected-FCF | 2.43 | |||||
| Price-to-DCF (Earnings Based) | 2.19 | |||||
| Price-to-Median-PS-Value | 0.69 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.71 | |||||
| Earnings Yield (Greenblatt) % | 3.82 | |||||
| FCF Yield % | -0.54 | |||||
| Forward Rate of Return (Yacktman) % | 7.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Swedish Orphan Biovitrum AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,933.243 | ||
| EPS (TTM) (€) | 0.657 | ||
| Beta | 0.57 | ||
| Volatility % | 31.07 | ||
| 14-Day RSI | 42.06 | ||
| 14-Day ATR (€) | 0.440638 | ||
| 20-Day SMA (€) | 22.73 | ||
| 12-1 Month Momentum % | 4.67 | ||
| 52-Week Range (€) | 16.098909 - 26.06 | ||
| Shares Outstanding (Mil) | 339.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Swedish Orphan Biovitrum AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Swedish Orphan Biovitrum AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Swedish Orphan Biovitrum AB Frequently Asked Questions
What is Swedish Orphan Biovitrum AB(STU:B6E)'s stock price today?
The current price of STU:B6E is €22.22. The 52 week high of STU:B6E is €26.06 and 52 week low is €16.10.
When is next earnings date of Swedish Orphan Biovitrum AB(STU:B6E)?
The next earnings date of Swedish Orphan Biovitrum AB(STU:B6E) is 2024-04-25.
Does Swedish Orphan Biovitrum AB(STU:B6E) pay dividends? If so, how much?
Swedish Orphan Biovitrum AB(STU:B6E) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers